Biopharma is wagering billions of dollars that CAR-T therapy can be easier. Will it work this time?

Large biopharma companies have spent over $4 billion in 2025 to buy startups working on in vivo CAR-T therapies as the first data in humans emerge. While it's still early days for in vivo cell ...